Minneapolis Heart Institute Foundation
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Minneapolis Heart Institute Foundation sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Minneapolis Heart Institute Foundation: 22 sponsored US clinical trials, 6 recruiting.
Minneapolis Heart Institute Foundation sponsors 22 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 9 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 2 trials.
Top-decile sponsor footprint
Minneapolis Heart Institute Foundation ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
Desifor-expand (mhif)
NCT06804980
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Progress Complication
NCT05100940
Progress Bifurcation Global Registry
NCT05100992
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
NCT04077762
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
NCT05187351
Coronary Computed Tomography Angiography (CCTA) for the Pre-procedural Planning of Percutaneous Coronary Intervention
NCT07691502
Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
NCT05440084
The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
NCT03542110
REduction of Contrast Via DyeVert Used in CTO Procedures
NCT03118544
Endovascular Aneurysm Repair (EVAR) Gate Study
NCT02934087
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
NCT01324453
Coronary Artery Disease (CAD) in Women Marathon Runners
NCT00918372
Alternative in Beta Blocker Intolerance: The ABBI Trial
NCT00893984
Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin
NCT00842374
Quality of Life in Patients With Refractory Angina
NCT00840437
Corticosteroid Pulse After Ablation
NCT00807586
Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures
NCT00806377
Post-conditioning to Reduce Infarct Size
NCT00755469
Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis
NCT00538759
Bone Marrow Stem Cell Infusion Following a Heart Attack
NCT00268307
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 4 | 4 |
What is open in the Minneapolis Heart Institute Foundation pipeline
6 recruiting of 22 indexed (27% open); 9 completed (41%).
Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Coronary Artery Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Minneapolis Heart Institute Foundation: open-pipeline peers nationwide
Peers matched on 22 registered trials and 27% open enrollment, not the therapeutic-area sidebar.
Minneapolis Heart Institute Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors near 27% open enrollment (± trial volume)
- Connecticut Children's Medical Center · 27% recruiting · 55 trials
- Criterium · 27% recruiting · 11 trials
- Nerviano Medical Sciences · 27% recruiting · 11 trials
- Neuronetics · 27% recruiting · 11 trials
Related
What to do with this Minneapolis Heart Institute Foundation page
22 registered trials is a research-attention snapshot, not an endorsement of Minneapolis Heart Institute Foundation or any single study.
- 6 of Minneapolis Heart Institute Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Minneapolis Heart Institute Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Minneapolis Heart Institute Foundation pipeline card: 22 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.